TRCT
OGEN icon

Tower Research Capital (TRC)’s Oragenics OGEN Stock Holding History

Tower Research Capital (TRC)’s Portfolio OGEN Stock Details OGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.55K Sell
4,548
-5
-0.1% -$4 ﹤0.01% 4459
2025
Q4 		$3.57K Buy
4,553
+4,345
+2,089% +$4.71K ﹤0.01% 4348
2025
Q3 		$272 Sell
208
-457
-69% -$578 ﹤0.01% 5044
2025
Q2 		$2.54K Buy
665
+416
+167% +$2.11K ﹤0.01% 4634
2025
Q1 		$1.57K Sell
249
-3
-1% -$26 ﹤0.01% 4690
2024
Q4 		$2.79K Sell
252
-1
-0.4% -$10 ﹤0.01% 4772
2024
Q3 		$2.89K Buy
253
+85
+51% +$2.4K ﹤0.01% 4924
2024
Q2 		$5.25K Sell
168
-27
-14% -$1.22K ﹤0.01% 4701
2024
Q1 		$8.44K Buy
195
+132
+210% +$13K ﹤0.01% 4017
2023
Q4 		$10.6K Sell
63
-37
-37% -$4.38K ﹤0.01% 4223
2023
Q3 		$8.89K Buy
100
+34
+52% +$3.4K ﹤0.01% 4289
2023
Q2 		$6.5K Buy
66
+1
+2% +$93 ﹤0.01% 4696
2023
Q1 		$6K Buy
65
+20
+44% +$3.33K ﹤0.01% 4857
2022
Q4 		$9K Buy
45
+22
+96% +$7.77K ﹤0.01% 4230
2022
Q3 		$9K Buy
23
+20
+667% +$11.7K ﹤0.01% 4675
2022
Q2 		$2K Buy
+3
New +$1.73K ﹤0.01% 5578
2021
Q2 		– Sell
-16
Closed -$26K – 5734
2021
Q1 		$26K Buy
16
+3
+23% +$5.45K ﹤0.01% 3682
2020
Q4 		$10K Buy
+13
New +$11.4K ﹤0.01% 4317
2020
Q3 		– Sell
-6
Closed -$7K – 5016
2020
Q2 		$7K Buy
+6
New +$5.9K ﹤0.01% 4158
2015
Q4 		– Hold
0
– – – 4887
2015
Q3 		– Hold
0
– – – 4553
2015
Q2 		– Hold
0
– – – 4841
2015
Q1 		– Hold
0
– – – 4771
2014
Q4 		– Hold
0
– – – 4496
2014
Q3 		– Hold
0
– – – 4753
2014
Q2 		– Hold
0
– – – 4469
2014
Q1 		– Hold
0
– – – 4784
2013
Q4 		– Hold
0
– – – 4031
2013
Q3 		– Hold
0
– – – 4330
2013
Q2 		– Hold
0
– – – 3494

Other funds holding OGEN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AAS
Ameritas Advisory Services Lincoln, Nebraska $2.58B AUM 18.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SJIM
St. Johns Investment Management Jacksonville, Florida $238M AUM 22.04% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Tower Research Capital (TRC)'s OGEN Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Oragenics (OGEN) stake by 0.11% in Q1 2026, selling an estimated $4 and leaving 4,548 shares worth $2.55K. The position accounts for ﹤0.01% of the portfolio, ranked #4459.

Tower Research Capital (TRC) first reported a position in OGEN in Q2 2020 and has held it in 19 quarters since. The position peaked at $26K in Q1 2021. 19 funds tracked by Wall St. Rank hold OGEN as of Q1 2026.

  • Tower Research Capital (TRC) held 4,548 shares of Oragenics worth $2.55K as of Q1 2026.
  • Tower Research Capital (TRC) sold 5 Oragenics shares in Q1 2026, an estimated $4.
  • Oragenics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4459 holding.
  • Tower Research Capital (TRC) first reported a position in Oragenics in Q2 2020 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Oragenics position peaked at $26K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Oragenics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.